Toshimichi Miya

1.2k total citations
42 papers, 968 citations indexed

About

Toshimichi Miya is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Toshimichi Miya has authored 42 papers receiving a total of 968 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Toshimichi Miya's work include Cancer therapeutics and mechanisms (12 papers), Lung Cancer Treatments and Mutations (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). Toshimichi Miya is often cited by papers focused on Cancer therapeutics and mechanisms (12 papers), Lung Cancer Treatments and Mutations (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). Toshimichi Miya collaborates with scholars based in Japan, United States and United Kingdom. Toshimichi Miya's co-authors include Yasutsuna Sasaki, Tomoyuki Goya, Fumio Nagashima, Masaru Narabayashi, Ryosuke Tsuchiya, Etsuo Miyaoka, Yukio Ando, Hisao Asamura, Hirokuni Yoshimura and Kaoru Shimokata and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Toshimichi Miya

40 papers receiving 943 citations

Peers

Countries citing papers authored by Toshimichi Miya

Since Specialization

Citations

This map shows the geographic impact of Toshimichi Miya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshimichi Miya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshimichi Miya more than expected).

Fields of papers citing papers by Toshimichi Miya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshimichi Miya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshimichi Miya. The network helps show where Toshimichi Miya may publish in the future.

Co-authorship network of co-authors of Toshimichi Miya

This figure shows the co-authorship network connecting the top 25 collaborators of Toshimichi Miya. A scholar is included among the top collaborators of Toshimichi Miya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshimichi Miya. Toshimichi Miya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy 2016 ·SpringerPlus ·(unknown), Toshimichi Miya, Kunihiko Kobayashi, Mitsunori Hino, Masahiro Ando, Susumu Takeuchi, Masahiro Seike, Kaoru Kubota, Akihiko Gemma	9
2	Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway 2015 ·Pulmonary Pharmacology & Therapeutics ·Koichiro Kamio, Jiro Usuki, Arata Azuma, Kuniko Matsuda, Takeo Ishii, Minoru Inomata, Hiroki Hayashi, Nariaki Kokuho, Kazue Fujita, Yoshinobu Saito, Toshimichi Miya, Akihiko Gemma	14
3	UGT1A11/28 and 1/6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer 2010 ·Cancer Chemotherapy and Pharmacology ·Yu Sunakawa, Wataru Ichikawa, Ken‐ichi Fujita, Fumio Nagashima, Hiroo Ishida, Keishi Yamashita, Keiko Mizuno, Keisuke Miwa, Kaori Kawara, Yuko Akiyama, Kazuhiro Araki, Wataru Yamamoto, Toshimichi Miya, Masaru Narabayashi, Yukio Ando, Takashi Hirose, Shigehira Saji, Yasutsuna Sasaki	33
4	CORRECTION TO “Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model” 2010 ·Drug Metabolism and Disposition ·Ken‐ichi Fujita, Yu Sunakawa, Keisuke Miwa, Yuko Akiyama, Minako Sugiyama, Kaori Kawara, Hiroo Ishida, Keishi Yamashita, Keiko Mizuno, Shigehira Saji, Wataru Ichikawa, Wataru Yamamoto, Fumio Nagashima, Toshimichi Miya, Masaru Narabayashi, Yukio Ando, Takashi Hirose, Yasutsuna Sasaki	27
5	Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer 2009 ·Cancer Chemotherapy and Pharmacology ·Ken‐ichi Fujita, Yukio Ando, Wataru Yamamoto, Toshimichi Miya, Hisashi Endo, Yu Sunakawa, Kazuhiro Araki, Keiji Kodama, Fumio Nagashima, Wataru Ichikawa, Masaru Narabayashi, Yuko Akiyama, Kaori Kawara, (unknown), Hiroyasu Ogata, Hiroyasu Iwasa, Yasushi Okazaki, Takashi Hirose, Yasutsuna Sasaki	82
6	Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas 2009 ·Annals of Oncology ·Ken‐ichi Fujita, Wataru Ichikawa, Wataru Yamamoto, H. Endo, Fumio Nagashima, Ryuhei Tanaka, Toshimichi Miya, Kazuhiro Araki, Keiji Kodama, Yu Sunakawa, Masaru Narabayashi, Keisuke Miwa, Yukio Ando, Yoshitsugu Akiyama, Kaori Kawara, Yosuke Sasaki	4
7	A case of respiratory akathisia in a cancer patient: A case report 2008 ·Palliative & Supportive Care ·Yu Sunakawa, Makoto Wada, Tomomi Nishida, (unknown), Kazuhiro Araki, Hisashi Endo, Fumio Nagashima, Wataru Ichikawa, Toshimichi Miya, Hideki Onishi, Masaru Narabayashi, Yasutsuna Sasaki	3
8	Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer 2008 ·British Journal of Cancer ·Yasuhide Yamada, Makoto Tahara, Toshimichi Miya, T. Satoh, Kuniaki Shirao, Yoshifumi Shimada, Atsushi Ohtsu, Yuka Sasaki, Yusuke Tanigawara	59
9	CYP2A6and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1 2008 ·Cancer Science ·Ken‐ichi Fujita, Wataru Yamamoto, (unknown), Hisashi Endo, Fumio Nagashima, Wataru Ichikawa, Ryuhei Tanaka, Toshimichi Miya, Kazuhiro Araki, Keiji Kodama, Yu Sunakawa, Masaru Narabayashi, Keisuke Miwa, Yukio Ando, Yuko Akiyama, Kaori Kawara, Tetsuya Kamataki, Yasutsuna Sasaki	46
10	Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A16 is associated with reduced activity for SN-38 in Japanese patients with cancer 2007 ·Cancer Chemotherapy and Pharmacology* ·Ken‐ichi Fujita, Yukio Ando, Fumio Nagashima, (unknown), (unknown), Kazuhiro Araki, Keiji Kodama, Toshimichi Miya, Masaru Narabayashi, Yasutsuna Sasaki	45
11	Novel Single Nucleotide Polymorphism of UGT1A9 Gene in Japanese 2006 ·Drug Metabolism and Pharmacokinetics ·Ken‐ichi Fujita, Yukio Ando, Fumio Nagashima, Wataru Yamamoto, Hisashi Endo, Keiji Kodama, Kazuhiro Araki, Toshimichi Miya, Masaru Narabayashi, Yasutsuna Sasaki	6
12	Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN‐38 glucuronidation in Japanese patients with cancer 2006 ·Cancer Science ·Kazuhiro Araki, Ken‐ichi Fujita, Yukio Ando, Fumio Nagashima, Wataru Yamamoto, Hisashi Endo, Toshimichi Miya, Keiji Kodama, Masaru Narabayashi, Yasutsuna Sasaki	76
13	Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study 2005 ·Lung Cancer ·Tomoyuki Goya, Hisao Asamura, Hirokuni Yoshimura, Harubumi Kato, Kaoru Shimokata, Ryosuke Tsuchiya, Yasunori Sohara, Toshimichi Miya, Etsuo Miyaoka	243
14	GEFITINIB (IRESSA) INHIBITS THE CYP3A4-MEDIATED FORMATION OF 7-ETHYL-10-(4-AMINO-1-PIPERIDINO)CARBONYLOXYCAMPTOTHECIN BUT ACTIVATES THAT OF 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO]CARBONYLOXYCAMPTOTHECIN FROM IRINOTECAN 2005 ·Drug Metabolism and Disposition ·Ken‐ichi Fujita, Yukio Ando, Masaru Narabayashi, Toshimichi Miya, Fumio Nagashima, Wataru Yamamoto, Keiji Kodama, Kazuhiro Araki, Hisashi Endo, Yasutsuna Sasaki	15
15	Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11 2001 ·Investigational New Drugs ·Toshimichi Miya, Tomoyuki Goya, Hirofumi Fujii, Tomoko Ohtsu, Kuniaki Itoh, Tadahiko Igarashi, Hironobu Minami, Yasutsuna Sasaki	31
16	The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide 1998 ·Cancer Chemotherapy and Pharmacology ·Toshimichi Miya, Tomoyuki Goya, Osamu Yanagida, Hiroshi Nogami, Yoshihiko Koshiishi, Yasutsuna Sasaki	15
17	A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38 1995 ·Japanese Journal of Cancer Research ·Yasutsuna Sasaki, Hideo Hakusui, Shoichi Mizuno, (unknown), Toshimichi Miya, Kenji Eguchi, (unknown), (unknown), Yuichiro Ohe, Nagahiro Saijo	60
18	Pharmacokinetic Study of Mitomycin C with Emphasis on the Influence of Aging 1992 ·Japanese Journal of Cancer Research ·Toshimichi Miya, (unknown), (unknown), Nagahiro Saijo	9
19	Feasibility Study on Quality-of-life Questionnaires for Patients with Advanced Lung Cancer 1992 ·Japanese Journal of Clinical Oncology ·(unknown), Miki Fukutani, (unknown), Kinuko Tajima, Yuka Tanaka, Chie Morioka, (unknown), Akira Kojima, Fumihiro Oshita, Toshimichi Miya, Hiroaki Okamoto, (unknown), Tomohide Tamura, Yasutsuna Sasaki, Tetsu Shinkai, Nagahiro Saijo	14
20	A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy 1992 ·Cancer Chemotherapy and Pharmacology ·Tetsu Shinkai, Kenji Eguchi, Yasutsuna Sasaki, Tomohide Tamura, Yuichiro Ohe, Akira Kojima, Fumihiro Oshita, Toshimichi Miya, Hiroaki Okamoto, (unknown), Nagahiro Saijo	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact